IL161326A0 - Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof - Google Patents

Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Info

Publication number: IL161326A0
Authority: IL; Israel
Prior art keywords: triazatetracyclo; pentaene; hexadeca; pharmaceutical compositions; succinic acid
Prior art date: 2001-11-29

Application number

IL16132602A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-29

Filing date

2002-10-21

Publication date

2004-09-27

2002-10-21 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-09-27 Publication of IL161326A0 publication Critical patent/IL161326A0/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL16132602A 2001-11-29 2002-10-21 Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof IL161326A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33424501P	2001-11-29	2001-11-29
PCT/IB2002/004380 WO2003045394A1 (en)	2001-11-29	2002-10-21	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (1)

Publication Number	Publication Date
IL161326A0 true IL161326A0 (en)	2004-09-27

Family

ID=23306297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16132602A IL161326A0 (en)	2001-11-29	2002-10-21	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Country Status (26)

Country	Link
US (1)	US6794388B2 (ja)
EP (1)	EP1461040B1 (ja)
JP (1)	JP4196829B2 (ja)
KR (1)	KR20040066140A (ja)
CN (1)	CN1589148A (ja)
AR (1)	AR037677A1 (ja)
AT (1)	ATE320256T1 (ja)
AU (1)	AU2002341327A1 (ja)
BR (1)	BR0214559A (ja)
CA (1)	CA2468705A1 (ja)
DE (1)	DE60209929T2 (ja)
DO (1)	DOP2002000512A (ja)
ES (1)	ES2258652T3 (ja)
GT (1)	GT200200236A (ja)
HN (1)	HN2002000332A (ja)
IL (1)	IL161326A0 (ja)
MX (1)	MXPA04003192A (ja)
PA (1)	PA8559401A1 (ja)
PE (1)	PE20030738A1 (ja)
PL (1)	PL374325A1 (ja)
RU (1)	RU2004116311A (ja)
SV (1)	SV2004001413A (ja)
TW (1)	TW200300345A (ja)
UY (1)	UY27548A1 (ja)
WO (1)	WO2003045394A1 (ja)
ZA (1)	ZA200402720B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1324013C (zh) *	1997-12-31	2007-07-04	辉瑞产品公司	芳基稠合氮杂多环化合物
EP1628685B1 (en)	2003-04-25	2010-12-08	Gilead Sciences, Inc.	Antiviral phosphonate analogs
MXPA05012507A (es) *	2003-05-20	2006-01-30	Pfizer Prod Inc	Composiciones farmaceuticas de vareniclina.
CN1870998B (zh) *	2003-10-27	2010-10-20	默沙东公司	Ccr-2拮抗剂盐
PL216369B1 (pl)	2004-07-27	2014-03-31	Gilead Sciences	Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
KR100734147B1 (ko) *	2005-07-29	2007-07-02	주식회사 엘지데이콤	호 알림 지연을 통한 멀티미디어 통화연결음 서비스 시스템및 방법
WO2007136650A2 (en) *	2006-05-16	2007-11-29	Gilead Sciences, Inc.	Method and compositions for treating hematological malignancies
WO2008060487A2 (en) *	2006-11-09	2008-05-22	Pfizer Products Inc.	Polymorphs of nicotinic intermediates
ES2360014T3 (es) *	2006-12-21	2011-05-31	Pfizer Products Inc.	Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina.
WO2009109651A1 (en) *	2008-03-06	2009-09-11	Medichem, S.A.	SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
WO2009143347A2 (en)	2008-05-22	2009-11-26	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
PE20110219A1 (es) *	2008-07-08	2011-03-31	Gilead Sciences Inc	Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
WO2010005643A1 (en) *	2008-07-10	2010-01-14	Teva Pharmaceutical Industries Ltd.	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010033045A1 (en) *	2008-09-16	2010-03-25	Igor Anatolievich Pomytkin	Compositions and methods for prevention or treatment of beta amyloid deposition
MY160005A (en) *	2008-12-11	2017-02-15	Cti Biopharma Corp	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20120093887A1 (en)	2009-06-10	2012-04-19	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en)	2009-06-22	2010-12-29	Teva Pharmaceutical Industries Ltd	Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
PL2837632T3 (pl)	2012-04-13	2017-01-31	Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.	Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
US9532944B2 (en)	2014-10-20	2017-01-03	Oyster Point Pharma, Inc.	Methods of improving ocular discomfort
US10709707B2 (en)	2016-04-07	2020-07-14	Oyster Point Pharma, Inc.	Methods of treating ocular conditions
EP3960740B1 (en)	2017-08-01	2023-11-15	Gilead Sciences, Inc.	Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1324013C (zh) *	1997-12-31	2007-07-04	辉瑞产品公司	芳基稠合氮杂多环化合物
HUP0202327A3 (en)	1999-08-27	2004-07-28	Inex Pharmaceuticals Corp Burn	Compositions for stimulating cytokine secretion and inducing an immune response
YU34501A (sh) *	2000-05-26	2003-10-31	Pfizer Products Inc.	Postupak reaktivne kristalizacije radi povećanja veličine čestica

2002
- 2002-10-21 ES ES02775143T patent/ES2258652T3/es not_active Expired - Lifetime
- 2002-10-21 KR KR10-2004-7008116A patent/KR20040066140A/ko not_active Application Discontinuation
- 2002-10-21 PL PL02374325A patent/PL374325A1/xx not_active Application Discontinuation
- 2002-10-21 BR BRPI0214559-6A patent/BR0214559A/pt not_active IP Right Cessation
- 2002-10-21 JP JP2003546896A patent/JP4196829B2/ja not_active Expired - Fee Related
- 2002-10-21 WO PCT/IB2002/004380 patent/WO2003045394A1/en active IP Right Grant
- 2002-10-21 AT AT02775143T patent/ATE320256T1/de not_active IP Right Cessation
- 2002-10-21 DE DE60209929T patent/DE60209929T2/de not_active Expired - Fee Related
- 2002-10-21 CN CNA028229304A patent/CN1589148A/zh active Pending
- 2002-10-21 MX MXPA04003192A patent/MXPA04003192A/es active IP Right Grant
- 2002-10-21 EP EP02775143A patent/EP1461040B1/en not_active Expired - Lifetime
- 2002-10-21 CA CA002468705A patent/CA2468705A1/en not_active Abandoned
- 2002-10-21 RU RU2004116311/04A patent/RU2004116311A/ru not_active Application Discontinuation
- 2002-10-21 AU AU2002341327A patent/AU2002341327A1/en not_active Abandoned
- 2002-10-21 IL IL16132602A patent/IL161326A0/xx unknown
- 2002-11-13 DO DO2002000512A patent/DOP2002000512A/es unknown
- 2002-11-22 GT GT200200236A patent/GT200200236A/es unknown
- 2002-11-25 TW TW091134190A patent/TW200300345A/zh unknown
- 2002-11-25 PE PE2002001130A patent/PE20030738A1/es not_active Application Discontinuation
- 2002-11-26 UY UY27548A patent/UY27548A1/es not_active Application Discontinuation
- 2002-11-27 HN HN2002000332A patent/HN2002000332A/es unknown
- 2002-11-27 AR ARP020104558A patent/AR037677A1/es unknown
- 2002-11-27 US US10/305,845 patent/US6794388B2/en not_active Expired - Fee Related
- 2002-11-28 SV SV2002001413A patent/SV2004001413A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559401A patent/PA8559401A1/es unknown
2004
- 2004-04-07 ZA ZA200402720A patent/ZA200402720B/en unknown

Also Published As

Publication number	Publication date
PE20030738A1 (es)	2003-08-28
GT200200236A (es)	2003-06-25
JP4196829B2 (ja)	2008-12-17
DOP2002000512A (es)	2003-05-31
SV2004001413A (es)	2004-05-07
KR20040066140A (ko)	2004-07-23
UY27548A1 (es)	2003-06-30
HN2002000332A (es)	2003-12-11
ATE320256T1 (de)	2006-04-15
PA8559401A1 (es)	2004-02-07
MXPA04003192A (es)	2004-07-27
CA2468705A1 (en)	2003-06-05
EP1461040B1 (en)	2006-03-15
WO2003045394A1 (en)	2003-06-05
US6794388B2 (en)	2004-09-21
DE60209929D1 (de)	2006-05-11
DE60209929T2 (de)	2006-11-16
TW200300345A (en)	2003-06-01
AU2002341327A1 (en)	2003-06-10
BR0214559A (pt)	2007-03-13
ES2258652T3 (es)	2006-09-01
JP2005513032A (ja)	2005-05-12
RU2004116311A (ru)	2005-03-27
PL374325A1 (en)	2005-10-17
ZA200402720B (en)	2005-05-18
CN1589148A (zh)	2005-03-02
AR037677A1 (es)	2004-12-01
EP1461040A1 (en)	2004-09-29
US20030149044A1 (en)	2003-08-07

Publication	Publication Date	Title
IL161326A0 (en)	2004-09-27	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HRP20030910A2 (en)	2004-02-29	Tartarate salts 5,8,14-triazatetracyclo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof
PL370913A1 (en)	2005-05-30	Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
HUP0302656A3 (en)	2009-08-28	Fumaric acid amides, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds
CA2326756A1 (en)	2000-08-24	Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
EP1741712A3 (en)	2007-04-04	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
HUP0400175A2 (en)	2007-07-30	Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity, their use and pharmaceutical compositions containing them
HK1067626A1 (en)	2005-04-15	Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
HUP0304085A3 (en)	2005-09-28	The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
WO2002048148A3 (en)	2003-05-01	Pyrazolopyridine derivatives
WO2003024933A1 (fr)	2003-03-27	Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
HUP0401773A3 (en)	2005-06-28	Use of [(2-amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkanacid derivatives for the preparation pharmaceutical compositions usable for treatment of pain
CA2442210A1 (en)	2002-10-10	Aryl oxime-piperazines useful as ccr5 antagonists
HUP0200729A3 (en)	2005-04-28	Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them
HUP0200605A3 (en)	2005-05-30	Hydroxamic acid derivatives, their preparation and use and pharmaceutical compositions containing them
HUP0401912A3 (en)	2007-02-28	Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
AU2002308369A1 (en)	2002-09-24	1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
HUP0103055A3 (en)	2003-07-28	New carboxylic acid amide compounds, process for their preparation and pharmaceutical compositions containing them and their use
HU0100987D0 (en)	2001-05-28	New propenecarboxylic acid amidoxime derivatives, process for their preparation and pharmaceutical compositions containing them